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SOMATOSTATIN RECEPTOR IMAGING 
The Presence of Somatostatin Receptors in Rheumatoid Arthritis 
P. M. VANHAGEN, H. M. MARKUSSE, S. W. J. LAMBERTS, D. J. KWEKKEBOOM, 
J. C. REUBI, and E. P. KRENNING 
Objective. To investigate the in vivo and in vitro 
expression of somatostatin receptors (SS-R) on synovial 
membranes of patients with rheumatoid arthritis (RA). 
Methods. The joints of 14 consecutive patients 
with active RA, 4 patients with severe osteoarthritis 
(OA), and 30 control patients were studied. The soma- 
tostatin analog [ll~In-DTPA-D-Phel]-octreotide was used 
for in vivo SS-R scintigraphy, and the somatostatin analog 
[125LTyr3]-octreotide for in vitro SS-R autoradiography. 
Results. Seventy-six percent (220 of 290) of the 
painful joints and 76% (207 of 274) of the swollen joints 
of the patients with RA were visualized by SS-R scintig- 
raphy. The degree of pain and swelling correlated well 
with positive scintigraphy findings in the joints (P < 
0.0001). In 2 of the RA patients who underwent scintig- 
raphy, as well as in 4 of 5 other patients, in vitro studies 
of the synovial membranes showed the presence of 
specific SS-R. In patients with OA, uptake of radio- 
activity in the affected joints was significantly lower than 
that in patients with RA. None of the joints of the 
control patients demonstrated uptake of radioactivity. 
Conchsion. SS-R are present in the synovial 
tissue of patients with active RA, as demonstrated by 
both in vivo and in vitro techniques. The potential value 
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of SS-R scintigraphy in the clinical evaluation of patients 
with active RA is presently unknown. 
Somatostatin is a small peptide, known to be a 
potent inhibitor of growth hormone release (1,2). It has 
recently been suggested that this neuropeptide is also 
involved in hematologic and granulomatous diseases 
such as malignant lymphoma, sarcoidosis, and tuber- 
culosis (3,4). Specific receptors for somatostatin 
(SS-R) have been found in activated lymphocytes, 
monocytes, and malignant lymphoid cells, by classic 
ligand-binding techniques as well as by in vitro auto- 
radiography (4-8). 
The somatostatin analog, [ I '  'In-DTPA-D-Phe'l- 
octreotide, has been used successfully for in vivo 
visualization of a variety of neuroendocrine tumors, as 
well as malignant lymphomas and granulomas 
(3,4,9,10). In 1 patient with sarcoidosis and arthralgia, 
we observed a high uptake of [" 'In-DTPA-D-Phe'l- 
octreotide in the affected joints. This observation led 
us to investigate the possible use of SS-R scintigraphy 
of affected joints in rheumatoid arthritis (RA). 
RA is characterized by synovitis. The histo- 
pathologic features lack uniformity, especially in more 
established disease, but diffuse lymphocytic infiltra- 
tion (predominantly CD4+ lymphocytes) and/or lym- 
phocytic aggregates positioned around postcapillary 
venules are present in most cases. We postulated that 
these activated lymphocytes and monocytes in syno- 
vial membranes express SS-R in sufficient numbers to 
allow in vivo visualization, as was the case in the 
disorders mentioned above. Herein we report our first 
results of SS-R scintigraphy of the joints in 14 consec- 
utive patients with active RA and 4 selected patients 
with severe osteoarthritis (OA) resembling RA. The 
synovial tissues of 2 of these patients with RA, as well 
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Table 1. Characteristics of the rheumatoid arthritis (RA) and osteoarthritis (OA) patients studied* 
No. of No. of No. of 
Patient Agelsex RF (mdhour) Treatment joints joints joints 
ESR swollen painful SS-R-positive 
RA 
1 72lF + 59 Corticosteroids, chloroquine, 17 12 24 
2 73/M + 28 Corticosteroids, chloroquine, 7 15 14 
NSAID 
NSAID 
3 67lF + 69 Corticosteroids, chloroquine, 34 23 34 
MTX. NSAID 
4 38lF - 30 Gold 34 34 27 
5 74lF - . Corticosteroids, sulfasalazine 10 16 14 
6 66lF + 39 NSAID 21 21 8 
7 55lF + 79 NSAID 6 6 8 
8 80lF + 66 NSAID 24 38 35 
9 521M + 56 Azathioprine, NSAID 14 19 31 
10 77lM + 94 NSAID 14 0 22 
11  65lF + 58 Corticosteroids, NSAID 10 14 33 
12 59lF - 48 D-penicillamine, 20 29 36 
13 68lM + 87 NSAID 30 28 20 
14 32lF + 80 Gold, NSAID 33 35 40 
15 68lF - 24 NSAID 12 I 6 
16 84lF - 18 Acetaminophen 1 7 6 
17 65lF - 12 None 12 17 6 
18 77lF - 10 NSAID 4 5 8 
corticosteroids, NSAID 
OA 
* RF = rheumatoid factor; ESR = erythrocyte sedimentation rate; SS-R = somatostatin receptor; 
NSAID = nonsteroidal antiinflammatory drug; MTX = methotrexate. 
as of 5 other patients, were investigated for the pres- 
ence of specific SS-R in vitro, using binding assays. 
PATIENTS AND METHODS 
Patients. Fourteen consecutive patients with RA that 
fulfilled the criteria of the American College of Rheuma- 
tology (formerly, the American Rheumatism Association) 
(11) and 4 selected patients with severe OA, all from the 
rheumatology department at Dr. Daniel den Hoed Clinic, 
were enrolled in the study after giving informed consent. 
Demographic and clinical characteristics of the patients are 
shown in Table 1.  Clinical evaluation of the joints was 
performed by a rheumatologist. The joints were scored for 
pain and swelling on a 0-3 scale, with 0 representing no 
swelling or pain and 3 representing extensive pain and 
swelling. Twenty patients with ophthalmic Graves' disease 
(OGD), 5 with neuroendocrine tumors, and 5 with malignant 
lymphomas were used as control patients. None of these 
patients had signs of arthritis, except for 1 patient with OGD 
who had severe generalized joint pains but no objective 
abnormalities found on physical examination. The joints of 
these control patients were scored according to their uptake 
of radioactivity, similar to the procedure in the patients with 
RA and OA. 
Scintigraphy. The somatostatin analog [DTPA-D- 
Phe'l-octreotide was obtained from Mallinckrodt (Petten, 
The Netherlands). [DTPA-D-Phe'l-octreotide was coupled 
to "'In as described previously (12). ["'In-DTPA-D-Phe'l- 
octreotide is excreted mainly through the kidneys, 90% of 
the dose being present in the urine 24 hours after injection. 
Because of its relatively long effective half-life, ["'In- 
DTPA-D-Phe'l-octreotide can be used to efficiently visualize 
SS-R-bearing lymphomas, granulomas, and neuroendocrine 
tumors after 24 hours when interfering background radio- 
activity is minimized by renal clearance (13,14). 
[' "In-DTPA-D-Phe'l-octreotide (248-360 MBq) was 
injected, and planar images were obtained with a large-field- 
of-view gamma camera (Counterbalance 3700 and ROTA 11; 
Siemens Gammasonics, Erlangen, Germany) equipped with 
a medium-energy collimator. Scanning was done for a preset 
time of 15 minutes, 24 hours after injection of the "'In- 
coupled somatostatin analog (14). To define the localizations 
of SS-R as visualized during this scanning procedure, the 
joints were scored on a 0-3 scale, where 0 = no uptake, 1 = 
low uptake, 2 = moderate uptake, and 3 = high uptake. The 
scintigrams of all patients were analyzed by 2 examiners who 
were not aware of the patient's identity, medical history, or 
outcomes of other investigations. In order to compare the 
number of lesions found by physical examination with those 
visualized during octreotide scintigraphy, the images were 
divided into easily recognizable parts. At physical examina- 
tion a total of 42 joints per patient had been evaluated: the 
shoulders, elbows, wrists, metacarpophalangeal (MCP) 
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Figure 1. Scintigraphy of the affected right wrist and the left second 
metacarpophalangeal and proximal interphalangeal joints of patient 
8 (anterior view, scanned 24 hours after administration of soma- 
tostatin analog). 
Figure 2. Scintigraphy of both affected elbows of patient 8 (scanned 
24 hours after administration of somatostatin analog). 
joints, distal interphalangeal joints, hips, knees, ankles, and 
metatarsophalangeal (MTP) joints. All of these joints were 
also evaluated and scored on the scintigrams. 
In vitro SS-R binding. The presence of SS-R in 
synovial tissue was investigated by autoradiography on lop  
thick frozen sections using an iodinated somatostatin octa- 
peptide analog, [ 1251-Tyr3]-octreotide. Tissue sections were 
mounted on precleaned microscope slides and stored at 
-20°C for at least 3 days to improve adhesion of tissue to the 
slide. Sections were then incubated for 2 hours at room 
temperature in the presence of the iodinated ligand (0.15- 
0.30 x lo6 disintegrations per minute/ml, or -80-160 pM). 
The incubation solution was 170 mM Tris HCl buffer, pH 
7.4, containing 1% bovine serum albumin (BSA), bacitracin 
(40 pdml), and MgC1, (5  mM). 
Nonspecific binding was determined by adding a 
1 pM solution of unlabeled octreotide. Incubated sections 
were washed twice for 5 minutes in cold incubation buffer 
containing 0,25% BSA and then in buffer alone, and dried 
quickly. The sections were exposed to 3H-labeled ultrafilms 
(Cambridge Research, Nussdorf, Germany) and maintained 
for 1 week in x-ray cassettes. Displacement experiments 
were done on successive sections of synovial membranes. In 
addition, saturation experiments using increasing concentra- 
tions of octreotide were performed on tissue sections incu- 
bated with 30,000 counts per minuteA00 pl radioligand. The 
autoradiograms were quantified using a computer-assisted 
image processing system. Tissue standards for iodinated 
Figure 3. Scintigraphy of the moderately painful and swollen right 
knee of patient 1 (anterior view, scanned 24 hours after adrninistra- 
tion of somatostatin analog). 
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Figure 4. Scintigraphy of the affected ankles and right forefoot of 
patient 7 (anterior view, scanned 24 hours after administration of 
somatostatin analog). 
compounds (Amersham, Aylesburg, England) were used for 
this purpose. 
Synovial tissue was designated SS-R positive when 
the optical density of the total-binding section was at least 
twice the optical density of the nonspecific-binding section. 
These techniques have been previously described in detail 
for various types of tumoral and nontumoral tissues (15-18). 
Autoradiography was performed on synovial biopsy speci- 
mens from 2 patients who underwent scintigraphy and 5 
other patients who did not undergo scintigraphy, from whom 
synovial membrane tissue was obtained in the course of a 
surgical procedure. 
RESULTS 
In normal individuals, physiologic accumula- 
tion of radioactivity is seen 24 hours after administra- 
tion of [’ “In-DTPA-D-Phe’l-octreotide in the pituitary 
and thyroid glands, the liver, the spleen, and the 
kidneys, as well as the bladder. Radioactivity at other 
sites is considered to be abnormal and indicates the 
presence of abnormal SS-R-positive tissue. Data on 
the 14 patients with RA and the 4 patients with OA are 
listed in Table 1 .  We observed uptake of [“‘In-DTPA- 
D-Phe’l-octreotide in a number of joints of all of the 
patients with RA (Figures 14). 
Table 2 illustrates the relationships between 
SS-R scintigraphy findings and pain and swelling in the 
RA patients. Five hundred seventy-six joints were 
scored on the scintigrams. In 2 patients a total of 12 
joints (all MTP joints in patient 1 and both shoulders in 
patient 11) could not be scored due to technical 
reasons. Two hundred twenty of the 290 painful joints 
in the 14 patients with RA (76%) were SS-R positive, 
whereas 125 of the remaining 286 nonpainful joints 
were also positive. Of the remaining 70 painful joints 
that were negative on the SS-R scan, 32 were in 2 
patients (patients 6 and 11). They did not differ from 
the other 12 patients with regard to either treatment or 
clinical symptoms. The median pain score was higher 
in the patients whose joints were positive by scintig- 
raphy (P < 0.0001, Wilcoxon rank sum test). The 
sensitivity of scintigraphy for swollen joints was also 
76% (207 of 274). Thirty-six of the 67 swollen joints 
that were negative by scintigraphy were also found in 
patients 6 and 1 1 .  Of 302 joints that were not swollen, 
138 were SS-R positive. The median degree of swelling 
correlated well with positivity by scintigraphy (P < 
0,0001, Wilcoxon rank sum test). The sensitivity of 
scintigraphy for painful and/or swollen joints was 74% 
(252 of 340) (Table 2). Ninety-three of 236 joints 
without clinical involvement (39%) were visualized. 
When the combination “pain and swelling” was 
scored, 80% of the joints (175 of 220) were positive by 
scintigraphy (Table 2). Uptake of radioactivity in the 
pericardium and pleurae of patient 13 was related to 
extraarticular RA involvement. 
In the OA patients, the sensitivity of scintigra- 
phy for joint swelling and joint pain was only 20% and 
14%, respectively, and the frequency of positive find- 
ings did not differ significantly between affected and 
clinically unaffected joints (P > 0.05, chi-square test). 
Table 2. Relationship between joint pain/swelling and somatostatin receptor scintigraphy results, in 14 patients with rheumatoid arthritis 
Pain Swelling Pain and/or swelling Pain and swelling 
Scintigraphy No Yes No Yes No Yes No Yes 
Negative 161 (56) 70 (24) 164 (54) 67 (24) 143 (61) 88 (26) 186 (52) 45 (20) 
Total 286 ( 100) 290 (100) 302 (100) 274 ( 100) 236 (100) 340 ( 1  00) 356 (100) 220 (loo) 
Positive 125 (44) 220 (76) 138 (46) 207 (76) 93 (39) 252 (74) 170 (48) 175 (80) 
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The median uptake of radioactivity in the OA patients 
was lower than that in the RA patients (85% of the OA 
group had a scintigraphy score of 1 ,  versus 36% of the 
RA group). In none of the control patients with OGD, 
neuroendocrine tumors, or malignant lymphomas was 
uptake of radioactivity observed in the joints. 
The presence of specific SS-R in surgically 
excised synovial tissue was confirmed by in vitro 
autoradiography in 2 patients with RA. Both joints had 
also been visualized in vivo by scintigraphy. The 
displacement curve shown in Figure 5 illustrates the 
high affinity and specificity of the ['251-Tyr3]-octreotide 
binding in studies with these synovial tissue sections. 
This suggests the presence of SS-R in the tissue. 
However, we were unable to identify by autoradio- 
graphic studies which cell type(s) expressed SS-R in 
this tissue. The presence of specific SS-R was confirmed 
in 4 of 5 other patients with active RA who did not 
undergo scanning, from whom MCP, knee, and ankle 
synovial membrane tissue samples were obtained. 
DISCUSSION 
SS-R scintigraphy has been used successfully in 
the visualization of neuroendocrine tumors as well as 
granulomatous diseases and malignant lymphomas 
(3,4,9,10). This is, to our knowledge, the first report of 
the use of this technique in the Visualization of clini- 
cally affected joints in RA. RA is a chronic inflammatory 
a, s 0 5 o j  
a, 
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Figure 5. In vitro detection of somatostatin receptors in a synovial 
tissue sample from a rheumatoid arthritis patient. Tissue sections 
were incubated with 30,000 counts per minute/100 pl radioligand and 
increasing concentrations of unlabeled octreotide or 100 p M  epider- 
mal growth factor (EGF). The displacement curve of '''1-[Tyr3]- 
octreotide is shown. spec. bind. = specific binding. 
disorder involving the synovial membranes of multiple 
joints. There is no "gold standard" for the assessment of 
the clinical activity of the disease. Subjective parame- 
ters are mainly used to quantify arthritis activity (19). 
Pain and swelling of the joints are the main clinical 
indicators of inflammatory activity in RA. In the 14 
patients with active RA examined in this study, clini- 
cal activity correlated well with the results of SS-R 
scintigraphy. However, in 2 patients, a number of 
painful and swollen joints were negative by scintigra- 
phy. The reason for this discrepancy in these 2 pa- 
tients is not clear. The number of false-positive scin- 
tigraphy results is unknown, because we did not 
perform synovial biopsies to exclude subclinical syno- 
vitis in these patients. Pleural and pericardial involve- 
ment of RA were visualized as well in 1 patient, 
suggesting that SS-R scintigraphy is also useful in the 
visualization of extraarticular involvement. 
In the selected patients with severe OA, no 
significant correlation between paidswelling and up- 
take of radioactivity by the affected joints at scintig- 
raphy was demonstrated. However, the osteoarthritic 
joints demonstrated a lower uptake of ['I 'In-DTPA-D- 
Phe'l-octreotide in comparison with the joints of the 
patients with RA. We cannot rule out the presence of 
an inflammatory component in the affected joints of 
these selected OA patients; this is substantiated by the 
finding of negative scan results in all of the control 
patients. 
Different scintigraphic techniques have been 
used over the years for the visualization of affected 
joints in RA (20-25). The markers used can be classi- 
fied according to the compartment involved. The vas- 
cular compartment reflects increased blood flow and 
interstitial extravasation, the bone compartment re- 
flects normal response to bone destruction, and the 
inflammatory compartment reflects infiltration of leuko- 
cytes. To our knowledge, no scintigraphic technique 
related to specific receptors in the affected synovial 
membranes in RA has been described previously. In 
vitro binding assays showed the presence of specific 
SS-R in synovial biopsy specimens from our patients, 
but autoradiography did not enable recognition of 
which cells expressed these SS-R. [ I '  'In-DTPA-D- 
Phe'l-octreotide may bind to SS-R on lymphocytes 
and monocytes that have infiltrated into the affected 
synovial membranes. The low-grade uptake of radio- 
activity in OA, which has only a minor inflammatory 
component, supports this hypothesis. 
The specificity of this in vivo method of SS-R 
visualization might be substantiated by investigation 
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of the effect of simultaneous administration of high- 
dose "cold" octreotide. However, our in vitro studies 
already demonstrated specific binding of octreotide, 
which could be completely prevented by the addition 
of excess "cold" octreotide, in the synovial mem- 
branes studied. 
The relationship to and possible role of SS-R 
expression in disorders of the immune system have 
been described previously ( 3 4 , 2 6 3 5 ) .  T and B lympho- 
cytes and monocytes express SS-R, and somatostatin 
has been shown to modulate the activity of the im- 
mune system (5-7,2628). At low concentrations, so- 
matostatin caused inhibition of the lectin-induced pro- 
liferation response of lymphocytes (2628).  Inhibition 
of cytotoxicity and of the release of cytokines by 
lymphocytes has also been described (29,30). Soma- 
tostatin suppresses immunoglobulin synthesis in 
Peyer's patches as well as by a myeloma cell line 
(31,32). Lymphoid cell lines of T cell origin have been 
shown to express SS-R (33). Somatostatin and SS-R 
have also been detected in schistosomiasis-induced 
murine granulomas (34,35). Treatment with the long- 
acting SS analog octreotide decreased the granuloma- 
tous response in this model by -45% (36). In 10 
patients with active RA, a transient beneficial effect 
was observed after direct intraarticular administration 
of somatostatin (37). This may be related to the 
inhibition of the release of substance P by nerve 
endings within these joints or by modulation of the 
activity of infiltrating immune cells. Thus, the poten- 
tial value of somatostatin in the treatment of RA, as 
well as in monitoring of disease activity, merits further 
exploration. 
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